
Immunocore Holdings (IMCR) Stock Forecast & Price Target
Immunocore Holdings (IMCR) Analyst Ratings
Bulls say
Immunocore Holdings is well-positioned for continued success with their ImmTAX platform that has shown positive results in the treatment of a variety of diseases, including mUUM, NSCLC, and autoimmune diseases. Additionally, the company has a strong pipeline of potential treatments in various stages of development, providing opportunities for continued growth. With the anticipated success of their lead product KIMMTRAK and potential future successes in other indications, Immunocore is expected to see significant revenue growth in the coming years. Their strong clinical data and favorable safety profile make them a promising player in the biotech industry.
Bears say
Immunocore Holdings is a commercial-stage biotech company with a deep pipeline in multiple areas, but its main product KIMMTRAK only targets a specific cancer and its other drugs still have a long way to go before approval. Additionally, the regulatory landscape for TCR-based therapeutics is relatively unknown and could impact development and approval timelines. A buy rating and price target of $75 may be premature due to uncertainty and limited market potential in the near-term.
This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.
Immunocore Holdings (IMCR) Analyst Forecast & Price Prediction
Start investing in Immunocore Holdings (IMCR)
Order type
Buy in
Order amount
Est. shares
0 shares